NBY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.496

Open

1.440

VWAP

1.39

Vol

254.61K

Mkt Cap

39.94M

Low

1.330

Amount

354.48K

EV/EBITDA(TTM)

--

Total Shares

26.63M

EV

32.40M

EV/OCF(TTM)

12.22

P/S(TTM)

--

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

Show More

Events Timeline

(ET)

2026-03-27

10:31:00

Coinbase and Better Launch Token-Backed Mortgages

2026-03-23 (ET)

2026-03-23

09:20:00

NovaBay Pharmaceuticals Renamed to Stablecoin Development Corporation, Ticker Changed to SDEV

2026-01-20 (ET)

2026-01-20

09:50:00

NovaBay Trading Resumes

2026-01-20

09:40:00

NovaBay Trading Halted Due to Volatility

2026-01-13 (ET)

2026-01-13

12:10:00

NovaBay Shares Drop 14.2% to $11.54

2026-01-13

10:10:00

NovaBay Shares Drop 17.1% to $11.15

2026-01-13

09:50:00

NovaBay Trading Resumes

2026-01-13

09:40:00

NovaBay Trading Halted Due to Volatility

2025-10-20 (ET)

2025-10-20

19:09:19

NovaBay Meets NYSE American Continued Listing Requirements Again

News

seekingalpha

03-23seekingalpha

NovaBay Pharmaceuticals Rebrands to Stablecoin Development Corporation

Benzinga

Netflix Reports Q4 Results, Q1 Guidance Misses Estimates

Benzinga

D.R. Horton Reports Q1 Net Income of $594.8M Exceeding Estimates

seekingalpha

01-20seekingalpha

NovaBay Pharmaceuticals (NBY) Announces $100M Stock Sale Agreement with Virtu Americas

Benzinga

J.B. Hunt Reports Q4 Revenue Slightly Below Estimates, Shares Drop 4.2%

Benzinga

RF Industries Reports $22.7M Q4 Sales, Shares Surge 21.4%

Valuation Metrics

The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY.A) is -6.83, compared to its 5-year average forward P/E of -1.91. For a more detailed relative valuation and DCF analysis to assess NovaBay Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.91

Current PE

-6.83

Overvalued PE

-0.34

Undervalued PE

-3.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-5.57

Current EV/EBITDA

-285.64

Overvalued EV/EBITDA

20.07

Undervalued EV/EBITDA

-31.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

1.45

Current PS

61.64

Overvalued PS

6.97

Undervalued PS

-4.08

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top loosers today

Intellectia · 908 candidates

Region: USPrice Change Pct: <= $-3.00

Ticker

Name

Market Cap$

Olema Pharmaceuticals Inc

1.70B

Oric Pharmaceuticals Inc

1.54B

Reviva Pharmaceuticals Holdings Inc

20.87M

EUDA Health Holdings Ltd

27.12M

Cardio Diagnostics Holdings Inc

9.68M

Traeger Inc

84.24M

pennys stocks with high return

Intellectia · 265 candidates

Price: $1.00 - $15.00List Exchange: XNYS, XNAS, XASEQuarter Price Change Pct: >= $25.00Monthly Average Dollar Volume: >= 200,000

Ticker

Name

Market Cap$

Creative Global Technology Holdings Ltd

70.49M

Erasca Inc

3.05B

Lipocine Inc

60.57M

Century Therapeutics Inc

434.23M

NovaBay Pharmaceuticals Inc

594.28M

Sidus Space Inc

234.80M

what stocks is up more than 500%

Intellectia · 22 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $500.00

Ticker

Name

Market Cap$

Sandisk Corp

73.47B

Regencell Bioscience Holdings Ltd

10.83B

Abivax SA

9.41B

Celcuity Inc

4.96B

Terns Pharmaceuticals Inc

3.99B

Hycroft Mining Holding Corporation

3.22B

Whales Holding NBY

Trading Trends

People Also Watch

Frequently Asked Questions

What is NovaBay Pharmaceuticals Inc (NBY) stock price today?

The current price of NBY is 1.35 USD — it has decreased -10

What is NovaBay Pharmaceuticals Inc (NBY)'s business?

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

What is the price predicton of NBY Stock?

Wall Street analysts forecast NBY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NovaBay Pharmaceuticals Inc (NBY)'s revenue for the last quarter?

NovaBay Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is NovaBay Pharmaceuticals Inc (NBY)'s earnings per share (EPS) for the last quarter?

NovaBay Pharmaceuticals Inc. EPS for the last quarter amounts to -1.34 USD, increased 139.29

How many employees does NovaBay Pharmaceuticals Inc (NBY). have?

NovaBay Pharmaceuticals Inc (NBY) has 2 emplpoyees as of March 30 2026.

What is NovaBay Pharmaceuticals Inc (NBY) market cap?

Today NBY has the market capitalization of 39.94M USD.